A Win For INZY
INZY (INZY:NASDAQ) soared at $7.54, representing a gain of 19.9%. On Thu, Dec 16, 2021, INZY:NASDAQ touched a New 2-Week Intraday High of $7.46. From Thu, Dec 02, 2021, the stock recorded 20.00% Up Days and 18.18% Green Days
About INZY (INZY:NASDAQ)
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
Top 10 Gainers:
- SPRB (SPRB:NASDAQ), 102.82%
- Genfit SA (GNFT:NASDAQ), 54.24%
- Bellerophon Therapeutics, Inc. (BLPH:NASDAQ), 34.6%
- IREN (IREN:NASDAQ), 26.25%
- GLTO (GLTO:NASDAQ), 22.61%
- ARQQ (ARQQ:NASDAQ), 21.98%
- SNCE (SNCE:NASDAQ), 20.14%
- INZY (INZY:NASDAQ), 19.87%
- EVTL (EVTL:NYSE), 19.44%
- Net 1 UEPS Technologies, Inc. (UEPS:NASDAQ), 19.39%